

## 10 RECOMBINANT SUBUNIT VACCINE

Clover Biopharmaceuticals is producing a recombinant subunit vaccine based on the trimeric S-protein of COVID-19.<sup>55</sup> The oral recombinant vaccine is being expanded by Vaxart in tablet formulation, using its proprietary oral vaccine platform.

## 11 CLINICAL MANAGEMENT AND TREATMENT

In severe COVID-19 cases, treatment should be given to support vital organ functions. People who think they may have been exposed to COVID-19 should contact their healthcare provider immediately. Healthcare personnel should care for patients in an Airborne Infection Isolation Room (AIIR). Precautions must be taken by the healthcare professional, such as contact precautions and airborne precautions with eye protection.<sup>56</sup>

Individuals with a mild clinical presentation may not require primary hospitalisation. Close monitoring is needed for the persons infected with COVID-19. Elderly patients and those prevailing chronic medical conditions such as